<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">37759674</PMID><DateCompleted><Year>2023</Year><Month>10</Month><Day>04</Day></DateCompleted><DateRevised><Year>2023</Year><Month>10</Month><Day>12</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2218-273X</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><Issue>9</Issue><PubDate><Year>2023</Year><Month>Aug</Month><Day>22</Day></PubDate></JournalIssue><Title>Biomolecules</Title><ISOAbbreviation>Biomolecules</ISOAbbreviation></Journal><ArticleTitle>Efficacy and Safety of Anti-SARS-CoV-2 Antiviral Agents and Monoclonal Antibodies in Patients with SLE: A Case-Control Study.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1273</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/biom13091273</ELocationID><Abstract><AbstractText>Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-related disease (COVID-19) has spread pandemically with high rates of morbidity and mortality. COVID-19 has also posed unprecedented challenges in terms of rapid development of pharmacological countermeasures to prevent or contrast SARS-CoV-2 pathogenicity. Anti-SARS-CoV-2 antiviral agents and monoclonal antibodies have been specifically designed to attenuate COVID-19 morbidity and prevent mortality in vulnerable subjects, such as patients with immune-mediated diseases, but evidence for the safe and effective use of these drugs in this latter population group is scarce. Therefore, we designed a retrospective, multicentre, observational, case-control study to analyse the impact of these treatments in COVID-19 patients with systemic lupus erythematosus (SLE), a paradigmatic, multi-organ autoimmune disease. We identified 21 subjects treated with antivirals and/or monoclonal antibodies who were matched with 42 untreated patients by age, sex, SLE extension and duration. Treated patients had higher baseline SLE disease activity index 2000 scores [SLEDAI-2K median (interquartile range) = 4 (1-5) vs. 0 (0-2); <i>p</i> = 0.009], higher prednisone doses [5 (0-10) mg vs. 0 (0-3) mg; <i>p</i> = 0.002], and more severe COVID-19 symptoms by a five-point World Health Organisation-endorsed analogue scale [1 (0-1) vs. 0 (0-1); <i>p</i> &lt; 0.010] compared to untreated patients. There was no difference between groups in terms of COVID-19 outcomes and sequelae, nor in terms of post-COVID-19 SLE exacerbations. Three subjects reported mild adverse events (two with monoclonal antibodies, one with nirmatrelvir/ritonavir). These data suggest that anti-SARS-CoV-2 antivirals and monoclonal antibodies might be safely and effectively used in patients with SLE, especially with active disease and more severe COVID-19 symptoms at presentation.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ramirez</LastName><ForeName>Giuseppe A</ForeName><Initials>GA</Initials><Identifier Source="ORCID">0000-0002-2889-366X</Identifier><AffiliationInfo><Affiliation>Unit of Immunology, Rheumatology, Allergy and Rare Diseases, IRCCS Ospedale San Raffaele, Via Olgettina 60, 20132 Milan, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Medicine, Universit&#xe0; Vita-Salute San Raffaele, Via Olgettina 58, 20132 Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gerosa</LastName><ForeName>Maria</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Clinical Science of Community Health, Research Center for Adult and Pediatric Rheumatic Diseases, Universit&#xe0; degli Studi di Milano, Via Festa del Perdono 7, 20122 Milan, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Unit of Rheumatology, ASST Gaetano Pini-CTO, Piazza Cardinale Andrea Ferrari 1, 20122 Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bellocchi</LastName><ForeName>Chiara</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0001-8326-7904</Identifier><AffiliationInfo><Affiliation>Referral Center for Systemic Autoimmune Diseases, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano, Via Francesco Sforza 35, 20122 Milan, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Science of Community Health, Section of Internal Medicine, Universit&#xe0; degli Studi di Milano, Via Festa del Perdono 7, 20122 Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arroyo-S&#xe1;nchez</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0002-7902-0527</Identifier><AffiliationInfo><Affiliation>Unit of Immunology, Rheumatology, Allergy and Rare Diseases, IRCCS Ospedale San Raffaele, Via Olgettina 60, 20132 Milan, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Immunology, Hospital Universitario 12 de Octubre, Av de C&#xf3;rdoba, 28041 Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Immunology, Instituto de Investigaci&#xf3;n Biom&#xe9;dica, Hospital Universitario 12 de Octubre, Av de C&#xf3;rdoba, 28041 Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Asperti</LastName><ForeName>Chiara</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Unit of Immunology, Rheumatology, Allergy and Rare Diseases, IRCCS Ospedale San Raffaele, Via Olgettina 60, 20132 Milan, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Medicine, Universit&#xe0; Vita-Salute San Raffaele, Via Olgettina 58, 20132 Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Argolini</LastName><ForeName>Lorenza M</ForeName><Initials>LM</Initials><AffiliationInfo><Affiliation>Department of Clinical Science of Community Health, Research Center for Adult and Pediatric Rheumatic Diseases, Universit&#xe0; degli Studi di Milano, Via Festa del Perdono 7, 20122 Milan, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Unit of Rheumatology, ASST Gaetano Pini-CTO, Piazza Cardinale Andrea Ferrari 1, 20122 Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gallina</LastName><ForeName>Gabriele</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0003-4285-5966</Identifier><AffiliationInfo><Affiliation>Unit of Immunology, Rheumatology, Allergy and Rare Diseases, IRCCS Ospedale San Raffaele, Via Olgettina 60, 20132 Milan, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Medicine, Universit&#xe0; Vita-Salute San Raffaele, Via Olgettina 58, 20132 Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cornalba</LastName><ForeName>Martina</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Clinical Science of Community Health, Research Center for Adult and Pediatric Rheumatic Diseases, Universit&#xe0; degli Studi di Milano, Via Festa del Perdono 7, 20122 Milan, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Unit of Rheumatology, ASST Gaetano Pini-CTO, Piazza Cardinale Andrea Ferrari 1, 20122 Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scotti</LastName><ForeName>Isabella</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Clinical Science of Community Health, Research Center for Adult and Pediatric Rheumatic Diseases, Universit&#xe0; degli Studi di Milano, Via Festa del Perdono 7, 20122 Milan, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Unit of Rheumatology, ASST Gaetano Pini-CTO, Piazza Cardinale Andrea Ferrari 1, 20122 Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Suardi</LastName><ForeName>Ilaria</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Clinical Science of Community Health, Research Center for Adult and Pediatric Rheumatic Diseases, Universit&#xe0; degli Studi di Milano, Via Festa del Perdono 7, 20122 Milan, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Unit of Rheumatology, ASST Gaetano Pini-CTO, Piazza Cardinale Andrea Ferrari 1, 20122 Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moroni</LastName><ForeName>Luca</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0001-8988-9106</Identifier><AffiliationInfo><Affiliation>Unit of Immunology, Rheumatology, Allergy and Rare Diseases, IRCCS Ospedale San Raffaele, Via Olgettina 60, 20132 Milan, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Medicine, Universit&#xe0; Vita-Salute San Raffaele, Via Olgettina 58, 20132 Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beretta</LastName><ForeName>Lorenzo</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0002-6529-6258</Identifier><AffiliationInfo><Affiliation>Referral Center for Systemic Autoimmune Diseases, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano, Via Francesco Sforza 35, 20122 Milan, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Science of Community Health, Section of Internal Medicine, Universit&#xe0; degli Studi di Milano, Via Festa del Perdono 7, 20122 Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bozzolo</LastName><ForeName>Enrica P</ForeName><Initials>EP</Initials><AffiliationInfo><Affiliation>Unit of Immunology, Rheumatology, Allergy and Rare Diseases, IRCCS Ospedale San Raffaele, Via Olgettina 60, 20132 Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Caporali</LastName><ForeName>Roberto</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Clinical Science of Community Health, Research Center for Adult and Pediatric Rheumatic Diseases, Universit&#xe0; degli Studi di Milano, Via Festa del Perdono 7, 20122 Milan, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Unit of Rheumatology, ASST Gaetano Pini-CTO, Piazza Cardinale Andrea Ferrari 1, 20122 Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dagna</LastName><ForeName>Lorenzo</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Unit of Immunology, Rheumatology, Allergy and Rare Diseases, IRCCS Ospedale San Raffaele, Via Olgettina 60, 20132 Milan, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Medicine, Universit&#xe0; Vita-Salute San Raffaele, Via Olgettina 58, 20132 Milan, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>08</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Biomolecules</MedlineTA><NlmUniqueID>101596414</NlmUniqueID><ISSNLinking>2218-273X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000911" MajorTopicYN="N">Antibodies, Monoclonal</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">antivirals</Keyword><Keyword MajorTopicYN="N">monoclonal antibodies</Keyword><Keyword MajorTopicYN="N">systemic lupus erythematosus</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>7</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>8</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>8</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>10</Month><Day>4</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>9</Month><Day>28</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>9</Month><Day>28</Day><Hour>1</Hour><Minute>2</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37759674</ArticleId><ArticleId IdType="pmc">PMC10527378</ArticleId><ArticleId IdType="doi">10.3390/biom13091273</ArticleId><ArticleId IdType="pii">biom13091273</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bastard P., Rosen L.B., Zhang Q., Michailidis E., Hoffmann H.H., Zhang Y., Dorgham K., Philippot Q., Rosain J., Beziat V., et al. Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science. 2020;370:eabd4585. doi: 10.1126/science.abd4585.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abd4585</ArticleId><ArticleId IdType="pmc">PMC7857397</ArticleId><ArticleId IdType="pubmed">32972996</ArticleId></ArticleIdList></Reference><Reference><Citation>Banerjee A., El-Sayes N., Budylowski P., Jacob R.A., Richard D., Maan H., Aguiar J.A., Demian W.L., Baid K., D&#x2019;Agostino M.R., et al. Experimental and natural evidence of SARS-CoV-2-infection-induced activation of type I interferon responses. iScience. 2021;24:102477. doi: 10.1016/j.isci.2021.102477.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.isci.2021.102477</ArticleId><ArticleId IdType="pmc">PMC8074517</ArticleId><ArticleId IdType="pubmed">33937724</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Q., Bastard P., Liu Z., Le Pen J., Moncada-Velez M., Chen J., Ogishi M., Sabli I.K.D., Hodeib S., Korol C., et al. Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. Science. 2020;370:eabd4570. doi: 10.1126/science.abd4570.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abd4570</ArticleId><ArticleId IdType="pmc">PMC7857407</ArticleId><ArticleId IdType="pubmed">32972995</ArticleId></ArticleIdList></Reference><Reference><Citation>Park A., Iwasaki A. Type I and Type III Interferons&#x2014;Induction, Signaling, Evasion, and Application to Combat COVID-19. Cell Host Microbe. 2020;27:870&#x2013;878. doi: 10.1016/j.chom.2020.05.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2020.05.008</ArticleId><ArticleId IdType="pmc">PMC7255347</ArticleId><ArticleId IdType="pubmed">32464097</ArticleId></ArticleIdList></Reference><Reference><Citation>Sette A., Crotty S. Adaptive immunity to SARS-CoV-2 and COVID-19. Cell. 2021;184:861&#x2013;880. doi: 10.1016/j.cell.2021.01.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2021.01.007</ArticleId><ArticleId IdType="pmc">PMC7803150</ArticleId><ArticleId IdType="pubmed">33497610</ArticleId></ArticleIdList></Reference><Reference><Citation>Rovere Querini P., De Lorenzo R., Conte C., Brioni E., Lanzani C., Yacoub M.R., Chionna R., Martinenghi S., Vitali G., Tresoldi M., et al. Post-COVID-19 follow-up clinic: Depicting chronicity of a new disease. Acta Biomed. 2020;91:22&#x2013;28. doi: 10.23750/abm.v91i9-S.10146.</Citation><ArticleIdList><ArticleId IdType="doi">10.23750/abm.v91i9-S.10146</ArticleId><ArticleId IdType="pmc">PMC8023087</ArticleId><ArticleId IdType="pubmed">32701913</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawano Y., Patel N.J., Wang X., Cook C.E., Vanni K.M., Kowalski E.N., Banasiak E.P., Qian G., DiIorio M., Hsu T.Y., et al. Temporal trends in COVID-19 outcomes among patients with systemic autoimmune rheumatic diseases: From the first wave through the initial Omicron wave. Ann. Rheum. Dis. 2022;81:1742&#x2013;1749. doi: 10.1136/ard-2022-222954.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/ard-2022-222954</ArticleId><ArticleId IdType="pmc">PMC9939910</ArticleId><ArticleId IdType="pubmed">35944947</ArticleId></ArticleIdList></Reference><Reference><Citation>Strangfeld A., Schafer M., Gianfrancesco M.A., Lawson-Tovey S., Liew J.W., Ljung L., Mateus E.F., Richez C., Santos M.J., Schmajuk G., et al. Factors associated with COVID-19-related death in people with rheumatic diseases: Results from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann. Rheum. Dis. 2021;80:930&#x2013;942. doi: 10.1136/annrheumdis-2020-219498.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2020-219498</ArticleId><ArticleId IdType="pmc">PMC7843211</ArticleId><ArticleId IdType="pubmed">33504483</ArticleId></ArticleIdList></Reference><Reference><Citation>Fung M., Babik J.M. COVID-19 in Immunocompromised Hosts: What We Know So Far. Clin. Infect. Dis. 2021;72:340&#x2013;350. doi: 10.1093/cid/ciaa863.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciaa863</ArticleId><ArticleId IdType="pmc">PMC7337668</ArticleId><ArticleId IdType="pubmed">33501974</ArticleId></ArticleIdList></Reference><Reference><Citation>Destras G., Bal A., Simon B., Lina B., Josset L. Sotrovimab drives SARS-CoV-2 omicron variant evolution in immunocompromised patients. Lancet Microbe. 2022;3:e559. doi: 10.1016/S2666-5247(22)00120-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2666-5247(22)00120-3</ArticleId><ArticleId IdType="pmc">PMC9142137</ArticleId><ArticleId IdType="pubmed">35636438</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun F., Lin Y., Wang X., Gao Y., Ye S. Paxlovid in patients who are immunocompromised and hospitalised with SARS-CoV-2 infection. Lancet Infect. Dis. 2022;22:1279. doi: 10.1016/S1473-3099(22)00430-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(22)00430-3</ArticleId><ArticleId IdType="pmc">PMC9282758</ArticleId><ArticleId IdType="pubmed">35843259</ArticleId></ArticleIdList></Reference><Reference><Citation>Qutub M., Aldabbagh Y., Mehdawi F., Alraddadi A., Alhomsy M., Alnahdi A., Fakeeh M., Maghrabi A., Alwagdani M., Bahabri N. Duration of viable SARS-CoV-2 shedding from respiratory tract in different human hosts and its impact on isolation discontinuation polices revision; A narrative review. Clin. Infect. Pract. 2022;13:100140. doi: 10.1016/j.clinpr.2022.100140.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clinpr.2022.100140</ArticleId><ArticleId IdType="pmc">PMC8848577</ArticleId><ArticleId IdType="pubmed">35190799</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathian A., Breillat P., Dorgham K., Bastard P., Charre C., Lhote R., Quentric P., Moyon Q., Mariaggi A.A., Mouries-Martin S., et al. Lower disease activity but higher risk of severe COVID-19 and herpes zoster in patients with systemic lupus erythematosus with pre-existing autoantibodies neutralising IFN-alpha. Ann. Rheum. Dis. 2022;81:1695&#x2013;1703. doi: 10.1136/ard-2022-222549.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/ard-2022-222549</ArticleId><ArticleId IdType="pubmed">35973806</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramirez G.A., Argolini L.M., Schioppo T., Sciascia S., Moroni L., Moroni G., Sinico R.A., Bonelli G., Alberici F., Mescia F., et al. Chronic glucocorticoid maintenance treatment is associated with the risk of SARS-CoV-2 infection in patients with systemic lupus erythematosus who received vaccination. Ann. Rheum. Dis. 2022;81:1476&#x2013;1477. doi: 10.1136/ard-2022-222832.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/ard-2022-222832</ArticleId><ArticleId IdType="pubmed">35922121</ArticleId></ArticleIdList></Reference><Reference><Citation>Dal-Re R., Becker S.L., Bottieau E., Holm S. Availability of oral antivirals against SARS-CoV-2 infection and the requirement for an ethical prescribing approach. Lancet Infect. Dis. 2022;22:e231&#x2013;e238. doi: 10.1016/S1473-3099(22)00119-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(22)00119-0</ArticleId><ArticleId IdType="pmc">PMC8963769</ArticleId><ArticleId IdType="pubmed">35364019</ArticleId></ArticleIdList></Reference><Reference><Citation>Cano-Munoz M., Polo-Megias D., Camara-Artigas A., Gavira J.A., Lopez-Rodriguez M.J., Laumond G., Schmidt S., Demiselle J., Bahram S., Moog C., et al. Novel chimeric proteins mimicking SARS-CoV-2 spike epitopes with broad inhibitory activity. Pt BInt. J. Biol. Macromol. 2022;222:2467&#x2013;2478. doi: 10.1016/j.ijbiomac.2022.10.031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijbiomac.2022.10.031</ArticleId><ArticleId IdType="pmc">PMC9546781</ArticleId><ArticleId IdType="pubmed">36220405</ArticleId></ArticleIdList></Reference><Reference><Citation>Beigel J.H., Tomashek K.M., Dodd L.E., Mehta A.K., Zingman B.S., Kalil A.C., Hohmann E., Chu H.Y., Luetkemeyer A., Kline S., et al. Remdesivir for the Treatment of COVID-19&#x2014;Final Report. N. Engl. J. Med. 2020;383:1813&#x2013;1826. doi: 10.1056/NEJMoa2007764.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2007764</ArticleId><ArticleId IdType="pmc">PMC7262788</ArticleId><ArticleId IdType="pubmed">32445440</ArticleId></ArticleIdList></Reference><Reference><Citation>Spinner C.D., Gottlieb R.L., Criner G.J., Arribas Lopez J.R., Cattelan A.M., Soriano Viladomiu A., Ogbuagu O., Malhotra P., Mullane K.M., Castagna A., et al. Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial. JAMA. 2020;324:1048&#x2013;1057. doi: 10.1001/jama.2020.16349.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.16349</ArticleId><ArticleId IdType="pmc">PMC7442954</ArticleId><ArticleId IdType="pubmed">32821939</ArticleId></ArticleIdList></Reference><Reference><Citation>Consortium W.H.O.S.T., Pan H., Peto R., Henao-Restrepo A.M., Preziosi M.P., Sathiyamoorthy V., Abdool Karim Q., Alejandria M.M., Hernandez Garcia C., Kieny M.P., et al. Repurposed Antiviral Drugs for COVID-19&#x2014;Interim WHO Solidarity Trial Results. N. Engl. J. Med. 2021;384:497&#x2013;511. doi: 10.1056/NEJMoa2023184.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2023184</ArticleId><ArticleId IdType="pmc">PMC7727327</ArticleId><ArticleId IdType="pubmed">33264556</ArticleId></ArticleIdList></Reference><Reference><Citation>Ader F., Bouscambert-Duchamp M., Hites M., Peiffer-Smadja N., Poissy J., Belhadi D., Diallo A., Le M.P., Peytavin G., Staub T., et al. Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): A phase 3, randomised, controlled, open-label trial. Lancet Infect. Dis. 2022;22:209&#x2013;221. doi: 10.1016/S1473-3099(21)00485-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(21)00485-0</ArticleId><ArticleId IdType="pmc">PMC8439621</ArticleId><ArticleId IdType="pubmed">34534511</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO Solidarity Trial Consortium Remdesivir and three other drugs for hospitalised patients with COVID-19: Final results of the WHO Solidarity randomised trial and updated meta-analyses. Lancet. 2022;399:1941&#x2013;1953. doi: 10.1016/S0140-6736(22)00519-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(22)00519-0</ArticleId><ArticleId IdType="pmc">PMC9060606</ArticleId><ArticleId IdType="pubmed">35512728</ArticleId></ArticleIdList></Reference><Reference><Citation>Gottlieb R.L., Vaca C.E., Paredes R., Mera J., Webb B.J., Perez G., Oguchi G., Ryan P., Nielsen B.U., Brown M., et al. Early Remdesivir to Prevent Progression to Severe COVID-19 in Outpatients. N. Engl. J. Med. 2022;386:305&#x2013;315. doi: 10.1056/NEJMoa2116846.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2116846</ArticleId><ArticleId IdType="pmc">PMC8757570</ArticleId><ArticleId IdType="pubmed">34937145</ArticleId></ArticleIdList></Reference><Reference><Citation>Jittamala P., Schilling W.H.K., Watson J.A., Luvira V., Siripoon T., Ngamprasertchai T., Almeida P.J., Ekkapongpisit M., Cruz C., Callery J.J., et al. Clinical antiviral efficacy of remdesivir in COVID-19: An open label, randomized, controlled adaptive platform trial (PLATCOV) J. Infect. Dis. 2023. Epub ahead of print .</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiad275</ArticleId><ArticleId IdType="pubmed">37470445</ArticleId></ArticleIdList></Reference><Reference><Citation>Jayk Bernal A., Gomes da Silva M.M., Musungaie D.B., Kovalchuk E., Gonzalez A., Delos Reyes V., Martin-Quiros A., Caraco Y., Williams-Diaz A., Brown M.L., et al. Molnupiravir for Oral Treatment of COVID-19 in Nonhospitalized Patients. N. Engl. J. Med. 2022;386:509&#x2013;520. doi: 10.1056/NEJMoa2116044.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2116044</ArticleId><ArticleId IdType="pmc">PMC8693688</ArticleId><ArticleId IdType="pubmed">34914868</ArticleId></ArticleIdList></Reference><Reference><Citation>Benaicha K., Khenhrani R.R., Veer M., Devi S., Shahbaz U., Salah Q.M., Hammad M., Palleti S.K. Efficacy of Molnupiravir for the Treatment of Mild or Moderate COVID-19 in Adults: A Meta-Analysis. Cureus. 2023;15:e38586. doi: 10.7759/cureus.38586.</Citation><ArticleIdList><ArticleId IdType="doi">10.7759/cureus.38586</ArticleId><ArticleId IdType="pmc">PMC10239651</ArticleId><ArticleId IdType="pubmed">37284377</ArticleId></ArticleIdList></Reference><Reference><Citation>Hammond J., Leister-Tebbe H., Gardner A., Abreu P., Bao W., Wisemandle W., Baniecki M., Hendrick V.M., Damle B., Simon-Campos A., et al. Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with COVID-19. N. Engl. J. Med. 2022;386:1397&#x2013;1408. doi: 10.1056/NEJMoa2118542.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2118542</ArticleId><ArticleId IdType="pmc">PMC8908851</ArticleId><ArticleId IdType="pubmed">35172054</ArticleId></ArticleIdList></Reference><Reference><Citation>Amani B., Amani B. Efficacy and safety of nirmatrelvir/ritonavir (Paxlovid) for COVID-19: A rapid review and meta-analysis. J. Med. Virol. 2023;95:e28441. doi: 10.1002/jmv.28441.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.28441</ArticleId><ArticleId IdType="pmc">PMC9880713</ArticleId><ArticleId IdType="pubmed">36576379</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang S., Hillyer C., Du L. Neutralizing Antibodies against SARS-CoV-2 and Other Human Coronaviruses. Trends Immunol. 2020;41:355&#x2013;359. doi: 10.1016/j.it.2020.03.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.it.2020.03.007</ArticleId><ArticleId IdType="pmc">PMC7129017</ArticleId><ArticleId IdType="pubmed">32249063</ArticleId></ArticleIdList></Reference><Reference><Citation>Konwarh R. Nanobodies: Prospects of Expanding the Gamut of Neutralizing Antibodies Against the Novel Coronavirus, SARS-CoV-2. Front. Immunol. 2020;11:1531. doi: 10.3389/fimmu.2020.01531.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.01531</ArticleId><ArticleId IdType="pmc">PMC7324746</ArticleId><ArticleId IdType="pubmed">32655584</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor P.C., Adams A.C., Hufford M.M., de la Torre I., Winthrop K., Gottlieb R.L. Neutralizing monoclonal antibodies for treatment of COVID-19. Nat. Rev. Immunol. 2021;21:382&#x2013;393. doi: 10.1038/s41577-021-00542-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-021-00542-x</ArticleId><ArticleId IdType="pmc">PMC8054133</ArticleId><ArticleId IdType="pubmed">33875867</ArticleId></ArticleIdList></Reference><Reference><Citation>de Almeida Oliveira A., Praia Borges Freire D., Rodrigues de Andrade A., de Miranda Marques A., da Silva Madeira L., Moreno Senna J.P., Freitas Brasileiro da Silveira I.A., de Castro Fialho B. The Landscape of Neutralizing Monoclonal Antibodies (nAbs) for Treatment and Prevention of COVID-19. J. Pharm. Innov. 2023. Epub ahead of print .</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12247-023-09713-w</ArticleId><ArticleId IdType="pmc">PMC9943047</ArticleId><ArticleId IdType="pubmed">36843665</ArticleId></ArticleIdList></Reference><Reference><Citation>Lafont E., Pere H., Lebeaux D., Cheminet G., Thervet E., Guillemain R., Flahault A. Targeted SARS-CoV-2 treatment is associated with decreased mortality in immunocompromised patients with COVID-19. J. Antimicrob. Chemother. 2022;77:2688&#x2013;2692. doi: 10.1093/jac/dkac253.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jac/dkac253</ArticleId><ArticleId IdType="pmc">PMC9384481</ArticleId><ArticleId IdType="pubmed">35876174</ArticleId></ArticleIdList></Reference><Reference><Citation>Gentile I., Scotto R., Schiano Moriello N., Pinchera B., Villari R., Trucillo E., Ametrano L., Fusco L., Castaldo G., Buonomo A.R., et al. Nirmatrelvir/Ritonavir and Molnupiravir in the Treatment of Mild/Moderate COVID-19: Results of a Real-Life Study. Vaccines. 2022;10:1731. doi: 10.3390/vaccines10101731.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines10101731</ArticleId><ArticleId IdType="pmc">PMC9607194</ArticleId><ArticleId IdType="pubmed">36298596</ArticleId></ArticleIdList></Reference><Reference><Citation>Faust J.S., Kumar A., Shah J., Khadke S., Dani S.S., Ganatra S., Sax P.E. Oral Nirmatrelvir and Ritonavir for COVID-19 in Vaccinated, Non-Hospitalized Adults, Ages 18&#x2013;50 Years. Clin. Infect. Dis. 2023. Epub ahead of print .</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciad400</ArticleId><ArticleId IdType="pubmed">37387690</ArticleId></ArticleIdList></Reference><Reference><Citation>Margalit I., Tiseo G., Ripa M., Borghi V., Green H., Prendki V., Riccardi N., Perego G.B., Grembiale A., Galli L., et al. Real-life experience with remdesivir for treatment of COVID-19 among older adults: A multicentre retrospective study. J. Antimicrob. Chemother. 2023;78:1505&#x2013;1509. doi: 10.1093/jac/dkad118.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jac/dkad118</ArticleId><ArticleId IdType="pubmed">37086215</ArticleId></ArticleIdList></Reference><Reference><Citation>Talarico R., Ramirez G.A., Barreira S.C., Cardamone C., Triggianese P., Aguilera S., Andersen J., Avcin T., Benistan K., Bertsias G., et al. ERN ReCONNET points to consider for treating patients living with autoimmune rheumatic diseases with antiviral therapies and anti-SARS-CoV-2 antibody products. Clin. Exp. Rheumatol. 2023;41:543&#x2013;553. doi: 10.55563/clinexprheumatol/jpargp.</Citation><ArticleIdList><ArticleId IdType="doi">10.55563/clinexprheumatol/jpargp</ArticleId><ArticleId IdType="pubmed">36916322</ArticleId></ArticleIdList></Reference><Reference><Citation>Calabrese C., Kirchner E., Villa-Forte A., Hajj-Ali R.A., Moss B.P., Fernandez J.P., Calabrese L. Early experience with tixagevimab/cilgavimab pre-exposure prophylaxis in patients with immune-mediated inflammatory disease undergoing B cell depleting therapy and those with inborn errors of humoral immunity. RMD Open. 2022;8:e002557. doi: 10.1136/rmdopen-2022-002557.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/rmdopen-2022-002557</ArticleId><ArticleId IdType="pmc">PMC9485640</ArticleId><ArticleId IdType="pubmed">36123015</ArticleId></ArticleIdList></Reference><Reference><Citation>Fragoulis G.E., Koutsianas C., Fragiadaki K., Mariolis I., Panopoulos S., Tsalapaki C., Pappa M., Dimitroulas T., Tektonidou M.G., Vassilopoulos D., et al. Oral antiviral treatment in patients with systemic rheumatic disease at risk for development of severe COVID-19: A case series. Ann. Rheum. Dis. 2022;81:1477&#x2013;1479. doi: 10.1136/annrheumdis-2022-222845.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2022-222845</ArticleId><ArticleId IdType="pubmed">35701154</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramirez G.A., Moroni L., Della-Torre E., Gerosa M., Beretta L., Bozzolo E.P., Dagna L. Systemic lupus erythematosus and COVID-19: What we know so far. Ann. Rheum. Dis. 2023;82:e73. doi: 10.1136/annrheumdis-2020-218601.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2020-218601</ArticleId><ArticleId IdType="pubmed">32859611</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization . Clinical Management of Severe Acute Respiratory Infection When Novel Coronavirus (nCoV) Infection Is Suspected: Interim Guidance. WHO; Geneva, Switzerland: 2020.</Citation></Reference><Reference><Citation>Ramirez G.A. Long COVID syndrome. Qeios. 2023 doi: 10.32388/PGG5QJ.</Citation><ArticleIdList><ArticleId IdType="doi">10.32388/PGG5QJ</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramirez G.A., Canti V., Moiola L., Magnoni M., Rovere-Querini P., Coletto L.A., Dagna L., Manfredi A.A., Bozzolo E.P. Performance of SLE responder index and lupus low disease activity state in real life: A prospective cohort study. Int. J. Rheum. Dis. 2019;22:1752&#x2013;1761. doi: 10.1111/1756-185X.13663.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/1756-185X.13663</ArticleId><ArticleId IdType="pubmed">31379114</ArticleId></ArticleIdList></Reference><Reference><Citation>Gerosa M., Schioppo T., Argolini L.M., Sciascia S., Ramirez G.A., Moroni G., Sinico R.A., Bonelli G., Alberici F., Mescia F., et al. The Impact of Anti-SARS-CoV-2 Vaccine in Patients with Systemic Lupus Erythematosus: A Multicentre Cohort Study. Vaccines. 2022;10:663. doi: 10.3390/vaccines10050663.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines10050663</ArticleId><ArticleId IdType="pmc">PMC9146432</ArticleId><ArticleId IdType="pubmed">35632419</ArticleId></ArticleIdList></Reference><Reference><Citation>Ciccimarra F., Luxi N., Bellitto C., Abbate L.L., De Nardo P., Savoldi A., Yeomans A., Molokhia M., Tacconelli E., Trifiro G. Exploring the Use of Monoclonal Antibodies and Antiviral Therapies for Early Treatment of COVID-19 Outpatients in a Real-World Setting: A Nationwide Study from England and Italy. BioDrugs. 2023;37:675&#x2013;684. doi: 10.1007/s40259-023-00601-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40259-023-00601-w</ArticleId><ArticleId IdType="pmc">PMC10163563</ArticleId><ArticleId IdType="pubmed">37148526</ArticleId></ArticleIdList></Reference><Reference><Citation>McGarry B.E., Sommers B.D., Wilcock A.D., Grabowski D.C., Barnett M.L. Monoclonal Antibody and Oral Antiviral Treatment of SARS-CoV-2 Infection in US Nursing Homes. JAMA. 2023;330:561&#x2013;563. doi: 10.1001/jama.2023.12945.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2023.12945</ArticleId><ArticleId IdType="pmc">PMC10349351</ArticleId><ArticleId IdType="pubmed">37450293</ArticleId></ArticleIdList></Reference><Reference><Citation>Calabrese C.M., Kirchner E., Husni E.M., Moss B.P., Fernandez A.P., Jin Y., Calabrese L.H. Breakthrough SARS-CoV-2 Infections in Patients With Immune-Mediated Disease Undergoing B Cell-Depleting Therapy: A Retrospective Cohort Analysis. Arthritis Rheumatol. 2022;74:1906&#x2013;1915. doi: 10.1002/art.42287.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.42287</ArticleId><ArticleId IdType="pmc">PMC9349969</ArticleId><ArticleId IdType="pubmed">35791921</ArticleId></ArticleIdList></Reference><Reference><Citation>Ordaya E.E., Beam E., Yao J.D., Razonable R.R., Vergidis P. Characterization of Early-Onset Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Immunocompromised Patients Who Received Tixagevimab-Cilgavimab Prophylaxis. Open Forum Infect. Dis. 2022;9:ofac283. doi: 10.1093/ofid/ofac283.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ofid/ofac283</ArticleId><ArticleId IdType="pmc">PMC9214166</ArticleId><ArticleId IdType="pubmed">35859990</ArticleId></ArticleIdList></Reference><Reference><Citation>Shahram F., Esalatmanesh K., Khabbazi A., Rezaieyazdi Z., Mirfeizi Z., Sadeghi A., Soroosh M., Kavosi H., Alikhani M., Mostafaei S. Coronavirus disease 2019 in patients with Behcet&#x2019;s disease: A report of 59 cases in Iran. Clin. Rheumatol. 2022;41:1177&#x2013;1183. doi: 10.1007/s10067-021-06004-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10067-021-06004-y</ArticleId><ArticleId IdType="pmc">PMC8628030</ArticleId><ArticleId IdType="pubmed">34842999</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahluwalia M., Givertz M.M., Mehra M.R. A proposed strategy for management of immunosuppression in heart transplant patients with COVID-19. Clin. Transplant. 2020;34:e14032. doi: 10.1111/ctr.14032.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ctr.14032</ArticleId><ArticleId IdType="pmc">PMC7361140</ArticleId><ArticleId IdType="pubmed">32621523</ArticleId></ArticleIdList></Reference><Reference><Citation>Naghashzadeh F., Shafaghi S., Sharif-Kashani B., Tabarsi P., Saliminejad L., Noorali S. Coronavirus disease 2019 outcomes in heart transplant recipients: A single-center case series. J. Med. Case Rep. 2021;15:453. doi: 10.1186/s13256-021-03028-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13256-021-03028-5</ArticleId><ArticleId IdType="pmc">PMC8435348</ArticleId><ArticleId IdType="pubmed">34511111</ArticleId></ArticleIdList></Reference><Reference><Citation>Calvo C., Udaondo C., Rheumatic Diseases E.-A.E.P.W.G. COVID-19 in Children With Rheumatic Diseases in the Spanish National Cohort EPICO-AEP. J. Rheumatol. 2021;48:1190&#x2013;1192. doi: 10.3899/jrheum.201548.</Citation><ArticleIdList><ArticleId IdType="doi">10.3899/jrheum.201548</ArticleId><ArticleId IdType="pubmed">33526617</ArticleId></ArticleIdList></Reference><Reference><Citation>Furlan A., Forner G., Cipriani L., Vian E., Rigoli R., Gherlinzoni F., Scotton P. Dramatic Response to Convalescent Hyperimmune Plasma in Association With an Extended Course of Remdesivir in 4 B Cell-Depleted Non-Hodgkin Lymphoma Patients With SARS-CoV-2 Pneumonia After Rituximab Therapy. Clin. Lymphoma Myeloma Leuk. 2021;21:e731&#x2013;e735. doi: 10.1016/j.clml.2021.05.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clml.2021.05.013</ArticleId><ArticleId IdType="pmc">PMC8139434</ArticleId><ArticleId IdType="pubmed">34217677</ArticleId></ArticleIdList></Reference><Reference><Citation>Bermas B.L., Gianfrancesco M., Tanner H.L., Seet A.M., Aguiar M.C., Al Adhoubi N.K., Al Emadi S., Cunha B.M., Flood R., Kusevich D.A., et al. COVID-19 in Pregnant Women With Rheumatic Disease: Data From the COVID-19 Global Rheumatology Alliance. J. Rheumatol. 2022;49:110&#x2013;114. doi: 10.3899/jrheum.210480.</Citation><ArticleIdList><ArticleId IdType="doi">10.3899/jrheum.210480</ArticleId><ArticleId IdType="pubmed">34470798</ArticleId></ArticleIdList></Reference><Reference><Citation>Bronstein Y., Adler A., Katash H., Halutz O., Herishanu Y., Levytskyi K. Evolution of spike mutations following antibody treatment in two immunocompromised patients with persistent COVID-19 infection. J. Med. Virol. 2022;94:1241&#x2013;1245. doi: 10.1002/jmv.27445.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.27445</ArticleId><ArticleId IdType="pmc">PMC8661643</ArticleId><ArticleId IdType="pubmed">34755363</ArticleId></ArticleIdList></Reference><Reference><Citation>Taha Y., Wardle H., Evans A.B., Hunter E.R., Marr H., Osborne W., Bashton M., Smith D., Burton-Fanning S., Schmid M.L., et al. Persistent SARS-CoV-2 infection in patients with secondary antibody deficiency: Successful clearance following combination casirivimab and imdevimab (REGN-COV2) monoclonal antibody therapy. Ann. Clin. Microbiol. Antimicrob. 2021;20:85. doi: 10.1186/s12941-021-00491-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12941-021-00491-2</ArticleId><ArticleId IdType="pmc">PMC8717300</ArticleId><ArticleId IdType="pubmed">34969393</ArticleId></ArticleIdList></Reference><Reference><Citation>Ocon A.J., Mustafa S.S. Real-World Experience of Tixagevimab and Cilgavimab (Evusheld) in Rheumatologic Patients on Rituximab. J. Clin. Rheumatol. 2023;29:109&#x2013;111. doi: 10.1097/RHU.0000000000001907.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/RHU.0000000000001907</ArticleId><ArticleId IdType="pubmed">36126256</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization  WHO Director-General&#x2019;s Opening Remarks at the Media Briefing&#x2014;5 May 2023.  [(accessed on 27 July 2023)].  Available online:  https://www.who.int/news-room/speeches/item/who-director-general-s-opening-remarks-at-the-media-briefing---5-may-2023.</Citation></Reference><Reference><Citation>Malahe S.R.K., Hoek R.A.S., Dalm V., Broers A.E.C., den Hoed C.M., Manintveld O.C., Baan C.C., van Deuzen C.M., Papageorgiou G., Bax H.I., et al. Clinical Characteristics and Outcomes of Immunocompromised Patients With Coronavirus Disease 2019 Caused by the Omicron Variant: A Prospective, Observational Study. Clin. Infect. Dis. 2023;76:e172&#x2013;e178. doi: 10.1093/cid/ciac571.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciac571</ArticleId><ArticleId IdType="pmc">PMC9384537</ArticleId><ArticleId IdType="pubmed">35869843</ArticleId></ArticleIdList></Reference><Reference><Citation>Ketkar A., Willey V., Pollack M., Glasser L., Dobie C., Wenziger C., Teng C.C., Dube C., Cunningham D., Verduzco-Gutierrez M. Assessing the risk and costs of COVID-19 in immunocompromised populations in a large United States commercial insurance health plan: The EPOCH-US Study. Curr. Med. Res. Opin. Curr. Med. Res. Opin. 2023;39:1103&#x2013;1118. doi: 10.1080/03007995.2023.2233819.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/03007995.2023.2233819</ArticleId><ArticleId IdType="pubmed">37431293</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramirez G.A., Argolini L.M., Bellocchi C., Moroni L., Della-Torre E., Farina N., Caporali R.F., Beretta L., Gerosa M., Bozzolo E.P., et al. Impact of the COVID-19 pandemic in patients with systemic lupus erythematosus throughout one year. Clin. Immunol. 2021;231:108845. doi: 10.1016/J.CLIM.2021.108845.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.CLIM.2021.108845</ArticleId><ArticleId IdType="pmc">PMC8405598</ArticleId><ArticleId IdType="pubmed">34478882</ArticleId></ArticleIdList></Reference><Reference><Citation>Hooijberg F., Boekel L., Vogelzang E.H., Leeuw M., Boers M., van Vollenhoven R., Lems W.F., Nurmohamed M.T., Wolbink G. Patients with rheumatic diseases adhere to COVID-19 isolation measures more strictly than the general population. Lancet Rheumatol. 2020;2:e583&#x2013;e585. doi: 10.1016/S2665-9913(20)30286-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2665-9913(20)30286-1</ArticleId><ArticleId IdType="pmc">PMC7579459</ArticleId><ArticleId IdType="pubmed">33106791</ArticleId></ArticleIdList></Reference><Reference><Citation>Talotta R., Atzeni F., Laska M.J. Retroviruses in the pathogenesis of systemic lupus erythematosus: Are they potential therapeutic targets? Autoimmunity. 2020;53:177&#x2013;191. doi: 10.1080/08916934.2020.1755962.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/08916934.2020.1755962</ArticleId><ArticleId IdType="pubmed">32321325</ArticleId></ArticleIdList></Reference><Reference><Citation>Joo Y.B., Kim K.J., Park K.S., Park Y.J. Influenza infection as a trigger for systemic lupus erythematosus flares resulting in hospitalization. Sci. Rep. 2021;11:4630. doi: 10.1038/s41598-021-84153-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-84153-5</ArticleId><ArticleId IdType="pmc">PMC7907068</ArticleId><ArticleId IdType="pubmed">33633288</ArticleId></ArticleIdList></Reference><Reference><Citation>Draborg A., Izarzugaza J.M., Houen G. How compelling are the data for Epstein-Barr virus being a trigger for systemic lupus and other autoimmune diseases? Curr. Opin. Rheumatol. 2016;28:398&#x2013;404. doi: 10.1097/BOR.0000000000000289.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/BOR.0000000000000289</ArticleId><ArticleId IdType="pubmed">26986247</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodrigues L., Bento Cunha R., Vassilevskaia T., Viveiros M., Cunha C. Drug Repurposing for COVID-19: A Review and a Novel Strategy to Identify New Targets and Potential Drug Candidates. Molecules. 2022;27:2723. doi: 10.3390/molecules27092723.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/molecules27092723</ArticleId><ArticleId IdType="pmc">PMC9099573</ArticleId><ArticleId IdType="pubmed">35566073</ArticleId></ArticleIdList></Reference><Reference><Citation>Pullmann R., Jr., Bonilla E., Phillips P.E., Middleton F.A., Perl A. Haplotypes of the HRES-1 endogenous retrovirus are associated with development and disease manifestations of systemic lupus erythematosus. Arthritis Rheum. 2008;58:532&#x2013;540. doi: 10.1002/art.23161.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.23161</ArticleId><ArticleId IdType="pubmed">18240231</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>